Syngene’s dedicated  model is the equivalent of having access to a full-fledged pharma company, housed in a single campus with capabilities across small molecules and biologics.

By identifying COVID-19 positive cases early on,  particularly those that are asymtomatic,  we can restrict further transmission of this deadly virus.

Syngene’s 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies. As a result, the  typical time from clinical candidate to regulatory filing is  just 11 months.